Regardless of the widespread use of new therapies, including the anti-vascular endothelial growth factor (VEGF) agents and corticosteroids, diabetic macular edema (DME) remains a common DR complication, and it is estimated to affect about 20% of the diabetic retinopathy patients in the United States [2]. Here, VEGFA is linked to diabetic macular edema.